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EDITORIAL
Effective prevention of mother-to-child transmission (PMTCT) 
programmes have dramatically reduced new paediatric HIV 
infections, and increasing access to antiretroviral therapy (ART) has 
substantially improved outcomes in infected children.[1-3] However, 
unmet needs persist in paediatric HIV infection.[4] In an ongoing 
study of early infant diagnosis and ART initiation following in utero 
transmission in KwaZulu-Natal Province, South Africa, we observe 
that the same factors predisposing to mother-to-child transmission 
(MTCT) in the current era of effective prevention are precisely those 
that militate against the success of ART for infected infants. Four 
cases are described to illustrate that the unmet needs of the high-risk 
mother have to be addressed urgently in order to achieve successful 
treatment of the infected child.
M1 is a 21-year-old mother who herself became HIV-infected as 
a result of MTCT. M1’s mother died from HIV-related conditions 
when M1 was 10 years of age. Disclosure of M1’s HIV status was at 
13 years. Thereafter, adherence became problematic as she navigated 
adolescence without parental support. Now living with her partner’s 
family, she feels unable to disclose her HIV status. At 18 years of age 
she had her first child, who died at 12 months, HIV status unknown. 
Two years later, she had a second child who was diagnosed as HIV-
infected on the day of birth; ART was initiated at 20 hours of age. 
Because M1 needed to hide the medication, giving ART to her 
baby was erratic. The child’s viral load (VL) became undetectable 
at 2  months of age, but rebounded the following month and has 
remained unstable since then.
M2 is a 17-year-old mother whose first child had been born 2 years 
previously with intrauterine HIV infection. M2 recently delivered 
her second baby at 28 weeks’ gestation after a pregnancy without 
antenatal care. This child is also HIV-infected. M2 lives at home 
with her parents, having left secondary school prematurely. She has 
suffered from substance abuse and partner violence. M2 and the first 
HIV-infected child remain virologically unsuppressed, although the 
first child achieved an undetectable VL at 2 months of age. The VL of 
the second child is not known.
M3 is a 30-year-old married woman. She and her husband both 
have secondary education and are both employed. M3 first tested 
HIV-positive at 28 weeks’ gestation and was told that taking ART 
would prevent the possibility of her transmitting the virus to her 
child. The baby’s initial HIV test was indeterminate and the VL 
was undetectable. Repeat testing confirmed that the baby was HIV-
infected. When told that the baby was infected, M3 said she had lost 
faith in ART, since she denied missing any doses during pregnancy. 
Subsequently, M3 has struggled to take her own therapy consistently 
or to administer ART to the infant, and both mother and child 
remain virally unsuppressed.
M4 is a 22-year-old mother who was orphaned in early childhood. 
Because of domestic violence at the hands of her extended family, she 
lived in a home of safety. She defaulted from ART prior to and during 
pregnancy owing to non-disclosure issues. She delivered a 1 400 g 
baby at 29 weeks’ gestation. The baby had an extended hospital stay 
because of multiple medical conditions associated with prematurity. 
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Table 1. Psychosocioeconomic and clinical factors influencing antiretroviral treatment outcome in four mother-child pairs 
following in utero HIV transmission
Patient features Case 1 Case 2 Case 3 Case 4
Mother
Psychosocial/family •  Loss of mother in 
childhood, lack of family 
support
•  Dependence on partner 
and partner’s family for 
accommodation
•  Non-disclosure to 
partner/partner’s family
• First child at age 18 years
•  Left school early – lack of 
education and life skills
• Substance abuse
• Partner violence
•  First child at age 15 years
•  Second child at age 17 
years
•  Stable, married, well 
educated; patient and 
husband employed
•  The ability of ART 
adherence to reduce the 
risk of MTCT was not 
fully explained
•  Orphaned in early 
childhood, lived in home 
of safety
•  Domestic violence in 
extended family
•  Non-disclosure to 
extended family prior to 
delivery
Clinical •  Chronic HIV infection 
from birth
•  Declining CD4+ cell 
count, persistent viraemia
• No antenatal care
•  Viraemia unsuppressed
•  VL 350 copies/mL 
at delivery; latest VL 
9 700 copies/mL
•  VL 330 000 copies/mL 
at delivery; latest VL 
<20 copies/mL at 1 month
Child
Psychosocial/family •  Sibling died at 12 months 
of age
•  Maternal non-disclosure, 
non-adherence
•  Two children with HIV 
infection
•  Maternal non-disclosure, 
non-adherence
•  Mother has lost faith in 
ART
•  Non-adherence despite 
disclosure
•  Mother reconciled with 
her family, facilitating 
disclosure and ART 
adherence
 Clinical • Persistent viraemia •  Younger sibling premature 
at 28 weeks’ gestation
• Persistent viraemia
•  Initial VL <100 copies/
mL; VL 1 600 copies/mL 
at 2 months
•  Premature at 29 weeks’ 
gestation, multiple 
neonatal complications
•  VL at birth 3 000 copies/
mL; VL <20 copies/mL at 
1 month
ART = antiretroviral therapy; MTCT = mother-to-child transmission; VL = viral load.
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The prolonged hospital stay provided an opportunity for interven-
tion including social worker involvement, allowing reconciliation 
between M4 and her partner’s family and disclosure of her HIV 
diagnosis to them. The baby initiated ART within the first 48 hours of 
life and reached an undetectable VL at 1 month of age. Both mother 
and baby have remained virologically suppressed to date without viral 
blips or rebound.
These four case studies illustrate several general features we 
have observed among the study cohort of in utero-infected infants 
and their mothers as a whole. In many cases the same factors that 
have destabilised the lives of mothers, and that contribute to HIV 
transmission, are those that interfere with effective treatment of HIV 
in the infants. In contrast, in the same setting in KwaZulu-Natal but 
15 years ago, in the era prior to effective PMTCT, ART adherence 
levels of ≥95% and virological suppression rates of 100% were seen 
in infants at 1 year post ART.[5] At that time, MTCT rates were high[2] 
and there was no self-selection for non-adherence in those mothers.
The psychosocioeconomic factors set out in Table 1 play a 
critical role in determining ART adherence and therefore virological 
suppression in mother and child. Central among these is non-
disclosure of HIV status to household members, as noted in other 
African studies.[4,6] The struggle for survival experienced by many 
of these women takes priority over risking disclosure of HIV status, 
since in many cases the mother is entirely dependent on her partner 
for the basic needs of food and housing. Striking a balance between 
the two fundamental life issues of caring for an HIV-infected child 
and personal survival requires an open dialogue between healthcare 
providers and receivers of healthcare.
The fourth case described above illustrates what can be achieved 
in difficult circumstances. In this instance, the child was premature 
and initially unwell, requiring many weeks of hospital admission. This 
provided the opportunity for relationships to be established between 
social workers and the family, ultimately resulting in a successful 
outcome. In contrast, what is more typically observed is the lost 
opportunity to achieve rapid suppression of viraemia in newborns 
diagnosed in the first days of life. Indeed, in case 3, the infant had 
undetectable plasma viraemia initially, having received trans-placental 
ART. However, despite the parents – unusually – being married, 
educated and employed, the mother had become disillusioned with 
ART, having been poorly counselled during pregnancy.
In summary, in the era of effective PMTCT, the same psycho-
socioeconomic factors that predispose to mother-to-child trans-
mission also substantially increase the likelihood of ART failure in 
infected infants. For this reason, maximal efforts now need to be 
invested in addressing the fundamental challenges faced by these 
high-risk mothers, since only then will the benefits of early infant 
diagnosis be fully realised.
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